|Home | About | Journals | Submit | Contact Us | Français|
This article has been retractedRetraction in:
Rationale: Nuclear factor erythroid 2–related factor 2 (Nrf2), an important regulator of lung antioxidant defenses, declines in chronic obstructive pulmonary disease (COPD). However, Nrf2 also regulates the proteasome system that degrades damaged and misfolded proteins. Because accumulation of misfolded proteins in the endoplasmic reticulum (ER) causes ER stress and ER stress-induced apoptosis, Nrf2 may potentially prevent ER stress-mediated apoptosis in COPD.
Objectives: To determine whether Nrf2-regulated proteasome function affects ER stress-mediated apoptosis in COPD.
Methods: We assessed the expression of Nrf2, Nrf2-dependent proteasomal subunits, proteasomal activity, markers of ER stress, and apoptosis in emphysematous lungs of mice exposed to cigarette smoke (CS) as well as peripheral lung tissues from normal control subjects and patients with COPD.
Measurements and Main Results: Compared with wild-type mice, emphysematous lungs of CS-exposed Nrf2-deficient mice exhibited markedly lower proteasomal activity and elevated markers of ER stress and apoptosis. Furthermore, compared with normal control subjects, lungs of patients with mild and advanced COPD showed a marked decrease in the expression of Nrf2-regulated proteasomal subunits and total proteasomal activity. However, they were associated with greater levels of ER stress and apoptosis markers. In vitro studies have demonstrated that enhancing proteasomal activity in Beas2B cells either by sulforaphane, an activator of Nrf2, or overexpression of Nrf2-regulated proteasomal subunit PSMB6, significantly inhibited cigarette smoke condensate (CSC)-induced ER stress and cell death.
Conclusions: Impaired Nrf2 signaling causes significant decline in proteasomal activity and heightens ER stress response in lungs of patients with COPD and CS-exposed mice. Accordingly, pharmacological approaches that augment Nrf2 activity may protect against COPD progression by both up-regulating antioxidant defenses and relieving ER stress.
Chronic obstructive pulmonary disease (COPD) continues to be a leading cause of death worldwide, but there are no successful treatment options available. Recent publications have highlighted the importance of defective nuclear factor erythroid 2–related factor 2 (Nrf2)-regulated antioxidant pathway as a mechanism of COPD pathogenesis.
The decline in Nrf2-dependent proteasomal activity in lungs of patients with COPD leads to an increase in endoplasmic reticulum stress, an unfolded protein response, and cell death that may participate in COPD progression.
Chronic obstructive pulmonary disease (COPD) is characterized by progressive, irreversible airflow limitation caused by emphysema, airway remodeling, and chronic bronchitis. COPD is a critical and rapidly increasing cause of death and morbidity worldwide (1) and is predicted to become the third leading cause of morbidity and mortality by 2020. The primary risk factor for COPD is tobacco smoking; other risk factors for COPD include wood fuel smoke, environmental air pollutants, respiratory infection (bacteria and virus), and aging. The pathobiology of COPD involves persistent inflammation, oxidative stress, impaired cell repair and cell death, and destruction of extracellular matrix (2). However, specific genes and underlying pathogenesis mechanisms that mediate development of COPD are elusive.
Endoplasmic reticulum (ER) is responsible for protein biosynthesis, correct folding, and post-translational modifications of secretory and membrane proteins. However, under physiological (increased secretory load) or pathological (oxidative stress, hypoxia, glucose starvation, alterations in calcium levels, and virus infection) stress, owing to increased protein influx, an accumulation of misfolded and unfolded proteins in ER lumen results in ER stress (3, 4). To restore protein homeostasis, ER stress triggers intracellular signal transduction referred to as unfolded protein response (UPR) through three ER transmembrane proteins: inositol-requiring protein-1, activating transcription factor-6, and protein kinase RNA (PKR)-like ER kinase (PERK) (5). These UPR transducers ameliorate ER stress by increasing ER chaperones, inhibiting translation, and retrograding transport of misfolded proteins to cytosol for degradation by the proteasome, in a process termed ER-associated protein degradation (ERAD) (6). Excess ER stress interferes with protein synthesis and secretion, induces reactive oxygen species generation, increases inflammation via nuclear factor-κB (NF-κB) activation, and mediates apoptotic cell death through the expression of transcription factor cytosine-cytosine-adenine-adenine-thymine enhancer-binding protein homologous protein (CHOP) (6). Due to the regulation of normal cellular processes and survival by ER, a growing body of evidence supports the role of ER stress in the pathophysiology of several chronic human inflammatory diseases, including neurodegenerative diseases, cardiovascular diseases, and diabetes (7–9). It has been previously reported that cigarette smoke (CS) causes ER stress in lungs of patients with COPD (10). Lung epithelial cells treated with CS extract induce ER stress and apoptosis (11). Furthermore, it is speculated that ER stress contributes to the pathogenesis of COPD (12).
Proteasome holoenzyme (26S proteasome), a multi-subunit complex, is a major disposal pathway for degradation of oxidized, unfolded, and misfolded proteins from ER and cytosol (13, 14). The 26S proteasome is composed of two major subcomplexes: the catalytic 20S proteasome and the regulatory 19S proteasome. Impaired or inhibited proteasomal activity disrupts ERAD and causes accumulation of misfolded proteins resulting in ER stress (15, 16). Impaired proteasome function has been implicated in several inflammatory and degenerative diseases. Surprisingly, the role of lung proteasome system in the pathogenesis of COPD has not been investigated (12).
Nuclear factor erythroid 2–related factor 2 (Nrf2), a bZIP transcription factor, disassociates from its cytoplasmic inhibitor Kelch-like ECH-associated protein 1 and binds to a cis-element antioxidant response element in its target gene promoters (17–19). It up-regulates a cytoprotective transcriptional program in response to a variety of physiological and/or pathological stresses (oxidative and inflammatory stress). Besides antioxidant defenses and xenobiotic detoxification enzymes, recent reports reveal Nrf2-dependent regulation of 26S proteasome system. Nrf2 activation by dithiolethione significantly up-regulated expression of several subunits of 20S and 19S proteasome in mice liver, which were attenuated in the absence of Nrf2 (20, 21). We and others previously reported that disruption of Nrf2 in mice impairs induction of these cytoprotective genes and augments CS-induced emphysema that was largely mediated by increased oxidative damage, inflammation, and apoptosis (22–24). More recently, we have demonstrated that pharmacological activation of Nrf2 ameliorates CS-induced emphysema by inhibiting oxidative stress and inflammation (25).
We and others have reported an inverse correlation of Nrf2 pathway in lungs and severity of COPD (26–28). Peripheral lung tissues and macrophages from smokers with COPD were associated with greater oxidative stress and lower antioxidant defenses due to impaired stability of Nrf2 protein. Although indisputable evidence associates impaired Nrf2 pathway with severity of COPD, underlying signaling mechanisms mediating the disease pathogenesis are not clear. The regulation of proteasome pathway by Nrf2 in lungs due to CS and modulation of ER stress by Nrf2-regulated proteasome system during COPD pathogenesis remains unclear. In the present study, we investigated the role of Nrf2-dependent proteasome system in regulation of ER stress during pathogenesis of COPD using mouse models and clinical samples.
Frozen peripheral lung tissue samples were obtained from the Division of Pulmonary and Critical Care Medicine, Department of Medicine, Temple University School of Medicine (Philadelphia, PA), from the Division of Cardiopulmonary Pathology, Department of Pathology, Johns Hopkins School of Medicine (Baltimore, MD), and from the NHLBI Lung Tissue Research Consortium (University of Colorado Health Sciences Center, Denver, CO). Clinical information, samples size, and classification based on Global Initiative for Chronic Obstructive Lund Disease stages (29) of patients with COPD and normal control subjects are summarized in Table 1. The study protocols were approved by the Institutional Review Board for human studies, and patients' lung function data from each of the contributing centers were obtained for this study.
Wild-type (Nrf2+/+) and Nrf2-disrupted (Nrf2−/−) female mice (CD-1 or C57BL/6 strain, 8–10 wk old) were exposed to CS for 5 h/d using a TE-10 smoking machine (Teague Enterprises, Davis, CA) and 3R4F reference cigarettes (University of Kentucky, Tobacco Research Institute, Lexington, KY) as described previously (26). The data represented for CD-1 mice are for 1 day and 1 week of CS exposure and 6 months of CS exposure for C57BL/6 mice. For the studies with the proteasome inhibitor, bortezomib (Velcade, Millenium Pharmaceuticals), a gift from the pharmacology department at Johns Hopkins School of Medicine, was administered intraperitoneally at a dose of 0.6 mg/kg body weight before CS exposure.
Human lung epithelial cells (Beas2B) were obtained from the American Type Culture Collection (Manassas, VA) and were cultured under recommended conditions. Cigarette smoke condensate (CSC) (dissolved in dimethyl sulfoxide, 40 mg/ml total particulate matter, nicotine content of 6%; kept at −80°C) was purchased from Murty Pharmaceuticals (Lexington, KY) (26). Beas2B cells were pretreated with Nrf2 activator, sulforaphane (10 μM), for 12 hours followed by CSC (200 μg/ml) or vehicle (dimethyl sulfoxide) for next 24 hours. For proteasome inhibition studies, cells were incubated with bortezomib (1 μM) for 4 hours before CSC treatment.
Lung homogenate or cell lysate (100 μg) was used to isolate proteasomes using proteasome isolation kit (Calbiochem, Gibbstown, NJ) following manufacturer's instructions and peptidase activity using proteasome SDS-activated activity assay (Calbiochem, Gibbstown, NJ). The fluorogenic peptides Suc-LLVY-AMC, BZ-VGR-AMC and Suc-LLE-AMC (75 μM each) were used as substrates to analyze the chymotrypsin-like, trypsin-like, and caspase-like activities of the proteasome.
Total RNA was extracted from tissues or cells using the Qiagen RNeasy kit (Qiagen, Valencia, CA) and quantitative real-time polymerase chain reaction (qRT-PCR) was performed using Assay-on-Demand primers and probe sets from Applied Biosystems (Foster City, CA) as described previously (24). We used the ABI 7000 Taqman system (Applied Biosystems) to perform these assays. β-actin was used as a normalization control.
Immunoblots were performed using antibodies for nicotinamide adenine dinucleotide reduced:quinone oxidoreductase 1 (NQO1) (Novus Biologicals, Littleton, CO), Nrf2, PSMA1, PSMB6, PSMD11, and phosphorylated-eukaryotic translation initiation factor 2α (P-eIF2α), CHOP, glyceraldehyde phosphate dehydrogenase (Santa Cruz Biotechnology, Santa Cruz, CA). All immunoblots were performed using protocols as described previously (26).
Formalin-fixed, paraffin-embedded lung tissue sections were used for immunohistochemical (IHC) and immunofluorescence (IF) analyses. Immunostaining staining for PSMB6 and CHOP was performed using an anti-PSMB6 monoclonal antibody and anti-CHOP polyclonal antibody (Santa Cruz Biotechnology) as described in the online supplement. Further, IF was used for colocalization studies for PSMB6 and different lung cell types as described in the online supplement.
Beas2B cells were transfected with Gaussia luciferase (Gluc) (pCMV-Gluc; Targeting Systems, El Cajon, CA) and renilla luciferase plasmids using lipofectamine (Invitrogen, Carlsbad, CA). Twenty-four hours after transfection, cells were treated as described above in the in vitro studies section. Gluc activity was measured using Gaussia Luciferase Assay Kit.
Caspase activity for caspase-3 and caspase-7 was measured using Apo-ONE homogeneous caspase-3 and caspase-7 assay kit (Promega, Madison, WI).
Beas2b cells were transfected with TrueClone plasmid for PSMB6 (SC322188, Origene Technologies, Inc., Rockville, MD) or vector control using manufacturer's protocol. Stable transfectants were selected using Neomycin (G418) and verified by q-RTPCR and Western blot analysis for PSMB6 expression.
Cell death was measured by MTT cell proliferation assay (Roche Diagnostics Corp., Indianapolis, IN) as per manufacturer's instructions.
Mean (standard deviation), median (interquartile range), and scatter plots were used to describe the data from human patients. Levels of Nrf2, NQO1, PSMA1, PSMB6, PSMD11 mRNA and protein; P-eIF2α, CHOP protein; proteasomal activity and caspase activity were analyzed for statistical significance and correlation studies. We used scatter plots to graphically display and Spearman correlation coefficients to evaluate the different relationships between mRNA and proteins as well as for the relationships of FEV1 as indicators of lung function. The relationship of proteasomal activity with lung function was further adjusted by age, smoking status, and pack-years using multivariable linear regression models.
In response to acute CS exposure (5 h), besides genes encoding antioxidant and xenobiotic detoxification enzymes, microarray analysis revealed up-regulation of several subunits of 20S and 19S proteasome subcomplex in the lungs of Nrf2+/+ mice but not in the lungs of Nrf2−/− mice (Table 2). Twelve proteasome genes were differentially expressed in the lungs of Nrf2+/+ mice after 5 hours of CS exposure. Selected proteasome genes (PSMA1, PSMB6, and PSMD11) were validated by qRT-PCR, and the data corroborated with the microarray analysis (Table 2).
Next, we investigated Nrf2-dependent proteasomal regulation in lungs after 1 week of CS exposure as well as in emphysematous lungs induced by 6 months of CS exposure. We selected to measure protein expression of PSMA1 and PSMB6 as indicators of the levels of proteasome in the lungs. Similar to acute exposure (5 h), Nrf2+/+ lungs showed markedly elevated levels of PSMA1, whereas mild induction was noted in Nrf2−/− lungs after 1 week of CS exposure (see Figures E1A and E1B in the online supplement). Besides proteasomal subunits, as expected, protein levels of NQO1 were up-regulated in response to CS only in Nrf2+/+ lungs (Table 2, Figures E1A and E1B). We had previously shown in a CD-1 strain of mice that CS exposure for 6 months caused markedly higher emphysema in Nrf2−/−, whereas Nrf2+/+ mice were resistant (22). More recently, in an emphysema-sensitive C57BL/6 background strain, we observed greater emphysema in Nrf2−/− mice and mild emphysema in Nrf2+/+ mice (25) after 6 months of CS exposure. Therefore, to determine the status of Nrf2-regulated proteasome system in emphysematous lungs, we chose to analyze PSMA1 and PSMB6 in lungs of Nrf2+/+ and Nrf2−/− mice in C57BL/6 background that were exposed to 6 months of CS (25). We noted marked increase in the protein expression of PSMA1 and PSMB6 in the lungs of Nrf2+/+ mice when compared with Nrf2−/− mice (Figures 1A and 1B). We and others have shown that emphysematous lungs are characterized with greater apoptosis in alveolar epithelial cells (22, 30–32) and endothelial cells (33, 34). To examine levels of proteasome in different cell types of emphysematous lungs, we analyzed the expression levels and localization of PSMB6 in emphysematous lungs of Nrf2+/+ and Nrf2−/− mice by IHC and IF (Figure 1D). Expression levels of PSMB6 was markedly higher in the parenchyma of emphysematous lungs of Nrf2+/+ mice, whereas levels in Nrf2−/− mice were similar to air-exposed groups. Furthermore, costaining with cell-specific markers showed greater expression of PSMB6 in alveolar epithelial cells (type I and type II epithelial cells) and endothelial cells in emphysematous lungs of Nrf2+/+ mice but not in Nrf2−/− mice (Figure 1D).
Next, to determine if differential expression of proteasomal subunits (PSMA1 and PSMB6) affects proteasome function, we analyzed the proteasomal activity in emphysematous lungs of CS-exposed mice. Proteasome 20S exhibits chymotrypsin-like, trypsin-like, and caspase-like proteolytic activities (35). Emphysematous lungs of Nrf2+/+ mice showed significantly elevated levels of proteasomal activity that included chymotrypsin-like, trypsin-like, and caspase-like proteolytic activities. On the contrary, emphysematous lungs of CS-exposed Nrf2−/− mice showed no significant change in proteasomal activity (Figure 1C) when compared with air-exposed mice. These results demonstrate that Nrf2 plays a critical role in regulation of proteasomal activity in lungs after cigarette smoke exposure, by transcriptional up-regulation of 20S proteasomal subunits essential for its function.
Impaired proteasomal function has been documented to induce ER stress because of accumulation of oxidized and/or aberrant (misfolded or unfolded) proteins due to compromised ERAD (15, 16). ER stress mediates pathogenesis of several inflammatory disorders, including CS-induced lung injury, by inducing cell death and inflammation (11, 34). Hence, we chose to investigate if decline in proteasomal activity in lungs of Nrf2−/− mice is associated with greater ER stress after chronic CS exposure. As a marker of ER stress, we measured P-eIF2α and CHOP protein expression in CS-exposed lungs of Nrf2+/+ and Nrf2−/− mice. CS exposure significantly increased ER stress in lungs of Nrf2−/− mice as compared with Nrf2+/+ mice measured after 1 week (Figures E2A and E2B) as well as 6 months (Figures 2A and 2B) of exposure. The expression levels of P-eIF2α and CHOP were markedly higher in 1 week CS-exposed lungs and emphysematous lungs of Nrf2−/− mice when compared with Nrf2+/+ mice (Figures 2A and 2B). IHC analysis also confirmed elevated levels of CHOP in emphysematous lungs of Nrf2−/− mice (Figure 2C).
Because CHOP mediates ER stress-induced apoptosis (36), next we analyzed apoptosis by measuring caspase (caspase-3 and caspase-7) activity in emphysematous lungs of Nrf2−/− and Nrf2+/+ mice. Consistent with CHOP expression, emphysematous lungs of Nrf2−/− mice showed threefold higher caspase activity when compared with the lungs of Nrf2+/+ mice (Figure 2D). Similar increase in caspase activity was observed in lungs exposed to CS for 1 week (Figure E2C).
To elucidate the involvement of defective proteasome function in sensitizing lung cells to ER stress after CS exposure, we treated wild-type (Nrf2+/+) mice with a proteasome inhibitor, bortezomib, 1 hour before CS exposure (5 h/d for 1 wk). Bortezomib-mediated proteasome inhibition lasted for 24 hours post-treatment (Figure E3). Bortezomib treatment alone caused mild ER stress as measured by increased protein levels of P-eIF2α and CHOP in lung lysates (Figure 3A). However, CS-induced expression of P-eIF2α and CHOP (P < 0.01) were further enhanced by bortezomib-mediated proteasome inhibition (P < 0.001) (Figure 3A). Bortezomib did not increase lung caspase activity; however, it enhanced CS-induced caspase activity approximately twofold (P < 0.001) (Figure 3B). These results indicate that proteasome inhibition predisposes cells to ER stress and apoptosis in smoker lungs.
We previously demonstrated impaired Nrf2 protein expression and transcriptional activity in the peripheral lung tissues of patients with advanced COPD (26). Nrf2 protein and Nrf2-dependent antioxidant defenses showed inverse correlation with worsening lung function (26). To determine if impaired Nrf2 expression affected proteasomal activity in lungs of patients with COPD, we measured Nrf2-regulated proteasomal subunits (PSMB6, PSMA1, and PSMD11) expression and total proteasomal activity in the lungs of patients with moderate, severe, and very severe COPD and normal control subjects. The clinical and demographic characteristics of the patients are shown in Table 1. For mRNA expression and total proteasomal activity analysis, lungs from (1) normal control subjects (5 nonsmokers, 4 ex-smokers, 8 smokers), (2) moderate COPD (0 nonsmokers, 5 ex-smokers, 7 smokers), (3) severe COPD (0 nonsmokers, 4 ex-smokers, 8 smokers), and (4) very severe COPD (0 nonsmokers, 9 ex-smokers, 15 smokers) were used. However, for protein expression by immunoblot analysis, 16 normal control subjects (5 nonsmokers, 3 ex-smokers, 8 smokers), 6 moderate COPD (all current smokers), and 16 very severe COPD (4 ex-smokers, 12 smokers) lung samples are represented (Figures 4C and 4D). Relative to lungs from normal control subjects, mRNA expression of PSMA1, PSMB6, and PSMD11 showed significant decline with COPD severity (Figure 4A). The mRNA expression of the proteasomal subunits decreases with declining lung function but was independent of smoking history (Figure 4B, wherein open circles are ex-smokers and solid circles are current smokers). Similarly, protein expression of PSMA1, PSMB6, and PSMD11 showed moderate repression in lungs of patients with mild COPD, whereas marked inhibition was noted in lungs from patients with advanced COPD when compared with lungs from normal control subjects (Figures 4C and 4D). Consistent with mRNA and protein expression of proteasomal subunits, we observed significant decline in total proteasomal activity in lungs with increasing COPD severity (Figure 4E). The lungs from patients with very severe as well as severe COPD showed a marked decline (~4.5-fold and ~4.0-fold, respectively), whereas lungs from patients with moderate COPD showed a moderate decline (~twofold) in proteasomal activity (chymotrypsin-like, trypsin-like, and caspase-like activities) compared with the lungs from normal control subjects (P < 0.001) (Figure 4E). Lungs from patients with very severe COPD and severe COPD also show significant decline in proteasomal activity when compared with lungs from patients with moderate COPD (P < 0.001) (Figure 4E). Correlation analysis showed a significant decline in proteasomal activity with worsening lung function, independent of smoking history (Figure 4F, wherein open circles are ex-smokers and solid circles are current smokers). After adjustment for smoking status and pack-years, total proteasomal activity was 1.04 (95% confidence interval, 0.89–1.18, P < 0.001) units decreased for a 10% decrease in FEV1. Proteasomal activity was not related to smoking status comparing ex-smokers versus current smokers with COPD or normal control subjects (P = 0.63), or to pack-years smoked (P = 0.77). Consistent with our previous findings (26), we observed a significant decline in Nrf2 protein expression (Figures 4C and 4D) as well as Nrf2-dependent antioxidant, NQO1 in the lungs of patients with COPD compared with the lungs of normal control subjects (Figure E4).
The data demonstrate a significant decline in proteasomal activity due to impaired Nrf2-mediated transcriptional regulation of proteasomal subunits in the lungs of patients with increasing COPD severity.
Next, we examined if the lungs of patients with increasing COPD severity are associated with greater ER stress-induced apoptosis. Compared with lungs from normal control subjects, we noted levels of P-eIF2α and CHOP in lungs were significantly higher in patients with moderate COPD, which was further elevated in patients with very severe COPD (Figures 5A and 5B). Correlation analysis showed an increase in the markers of ER stress (P-eIF2, CHOP) with worsening lung function, independent of the smoking history of the patients (Figure 5C and Figure E5). To determine if elevated CHOP expression is associated with greater apoptosis, we measured caspase-3 and caspase-7 activity in peripheral human lung tissues from normal control subjects and patients with moderate, severe, and very severe COPD. Consistent with CHOP protein levels, we observed a significant increase in caspase activity in the lung tissues with increasing COPD severity (Figure 5D). These results suggest a causal relationship between ER stress-induced apoptosis in COPD.
To determine if enhanced Nrf2-dependent proteasomal activity protects against CS-induced ER stress, Beas2B were treated with Nrf2 activator sulforaphane and were exposed to CSC. We have previously shown that sulforaphane activates Nrf2-dependent cytoprotective pathways in the human lung cell line (26). Sulforaphane treatment produced a time-dependent increase in chymotrypsin-like proteasomal activity in Beas2B cells (Figure E6). CSC treatment of Beas2b cells significantly up-regulated CHOP levels that were elevated further by bortezomib pretreatment (P < 0.001; Figures 6A and 6B). However, sulforaphane pretreatment for 24 hours attenuated CSC-induced CHOP expression that was significantly ablated in the presence of bortezomib (P < 0.001; Figure 6A and 6B).
Next, we analyzed if CHOP expression corresponds to cell death as measured by MTT assay in response to CSC. Indeed, CSC treatment significantly induced cell death that was enhanced further with bortezomib pretreatment (Figure 6C). Sulforaphane pretreatment rescued Beas2B cells from CSC treatment but this rescue was attenuated (~ fourfold, P < 0.001) in the presence of bortezomib (Figure 6C).
Besides apoptosis, ER stress impairs cellular protein secretory pathway. Hence, we investigated if activation of Nrf2 by sulforaphane in Beas2b cells repairs the impaired protein secretory pathway, by assaying the secretion of Guassia luciferase (Gluc) reporter in the cell-free conditioned medium. CSC treatment significantly reduced luciferase secretion that was further worsened by bortezomib pretreatment as monitored by luciferase activity in the media (P < 0.001; Figure 6D). On the other hand, sulforaphane pretreatment significantly restored CSC-induced decline in luciferase activity that was again attenuated in the presence of bortezomib (Figure 6D). Altogether, these results suggest that Nrf2 activation limits ER stress-mediated cellular perturbations by up-regulating proteasomal activity.
To determine if Nrf2-regulated proteasomal subunits modulate total proteasomal activity and to verify that enhancing proteasomal activity alone is sufficient to protect against CS-induced ER stress and cell death, we overexpressed PSMB6 in bronchial epithelial cell line, Beas2B (Figure 7A). PSMB6 overexpression significantly elevated total proteasomal activity (including chymotrypsin-like, trypsin-like, and caspase-like activities) when compared with vector control (Figure 7B).
When exposed to increasing concentrations of CSE, PSMB6 overexpressing Beas2b cells showed significant resistance to CSC-induced CHOP expression and cell death (Figures 7C and 7D). Activation of the proteasome has been associated with higher Nf-κB–mediated inflammatory response (37). To analyze whether enhancing proteasomal activity by overexpression of PSMB6 augmented CSC-induced inflammation, we measured IL-8 levels in the cell-free media after CSC treatment. The IL-8 levels were similar between vector control and PSMB6-overexpressing cells (Figure E7). Overall these observations substantiate the importance of Nrf2-dependent proteasomal subunit–driven proteasomal activity in protection against cigarette smoke–induced stress.
Oxidative stress contributes importantly to COPD pathogenesis (2, 38, 39). After several years of smoking, lungs of smokers with COPD are associated with elevated levels of markers of oxidative stress, compared with healthy smokers (26). The underlying defective signaling pathways that contribute to enhanced pathological damage and progression of COPD are not well understood. Previously, we and others have reported a defective Nrf2 signaling pathway in the lungs of patients with COPD (26–28) that represents a critical “molecular switch” in the regulation of cellular antioxidant defenses in the lungs of smokers. Repression of Nrf2 activity was associated with impaired antioxidant defenses and greater oxidative stress in COPD lungs. In the present study, using wild-type and Nrf2−/− mouse models, we report that (1) proteasome function is important for alleviating ER stress and ER stress–induced apoptosis in lungs of smokers, (2) Nrf2 regulates proteasomal activity by transcriptional regulation of critical proteasomal subunits in the lungs of nonemphysematous smokers and emphysematous smokers, and (3) Nrf2-dependent regulation of proteasome is critical for inhibiting ER stress and ER stress–induced apoptosis in the lungs of smokers. Furthermore, using peripheral lung tissue from patients with COPD and normal control subjects, we demonstrated that defective Nrf2-dependent proteasome heightened ER stress in lungs with increasing COPD severity. Finally, using a human bronchial epithelial cell line, we showed that enhancing Nrf2-dependent proteasomal activity by sulforaphane or overexpression of Nrf2-regulated proteasomal subunit PSMB6 attenuates CSC-induced ER stress and cell death.
Oxidatively damaged, misfolded/unfolded proteins are rapidly degraded by the ubiquitin-proteasome system (40). However, impaired proteasome function augments cellular stress and cytotoxicity (41). Cigarette smoke contains approximately 1015 free radicals and electrophiles per puff, and lung cells of smokers are prone to protein oxidative damage and hence require a robust proteasome system to combat cellular stress. We observed greater levels of protein carbonyls, a marker of oxidative damage to proteins, in lungs of CS-exposed mice (Figure E7 and E8). Surprisingly, the status of the proteasome system in lungs of smokers has not been addressed. In the present study, we observed transcriptional induction of numerous proteasomal subunits in the lungs of mice after acute CS exposure as shown in Table 1. Recently, Nrf2 has been shown to transcriptionally regulate critical subunits of 20S proteasomal subunits, including PSMB6 and PSMA1 (17, 42). Accordingly, we noted up-regulation of proteasomal subunits in an Nrf2-dependent manner. Disruption of Nrf2 abrogated transcriptional induction of several critical regulatory proteasomal subunits in lungs of mice. Protein expression of selected Nrf2-regulated proteasomal subunits (PSMB6 and PSMA1) remained elevated in lungs of Nrf2+/+ mice and minimal induction was observed in the lungs of Nrf2−/− mice after both 1 week and 6 months of CS exposure. Proteolytic core complex 20S proteasome displays chymotrypsin-like, trypsin-like, and caspase-like proteolytic activities that constitute the total proteasomal activity (37). In response to CS exposure for either 1 week or 6 months, we observed a significant increase in total proteasomal activity in the lungs of Nrf2+/+ mice, whereas lungs from Nrf2−/− mice showed a mild but significant increase in caspase-like proteolytic activity alone with no induction in either chymotrypsin-like or trypsin-like proteolytic activities. Proteasomal activity was similar in air-exposed lungs of Nrf2+/+ and Nrf2−/− mice. These results suggest a significant impairment in the ability of Nrf2−/− mice to remove damaged proteins from lung cells in response to CS.
Previously, we reported that the Nrf2 protein is markedly reduced in lungs of patients with COPD partly due to a decrease in expression of its positive regulator, DJ-1 (26). Therefore, we chose to determine the expression and activity of the Nrf2-dependent proteasome in the lungs of people with and without COPD. In contrast to normal control subject lungs, we observed marked repression in Nrf2-regulated proteasomal subunits PSMB6, PSMA1, and PSMD11, as well as a significant decline in lung proteasomal activity with increasing COPD severity. Our mouse studies displayed that pharmacological activation of Nrf2 by sulforaphane enhances proteasome activity in Nrf2+/+ lungs but not in Nrf2−/− lungs. These results suggest that the up-regulation of Nrf2-dependent proteasomal activity was not limited to a CS-mediated response, and thus Nrf2 is a potential target for enhancing proteasomal activity. Overall, our results indicate that a decline in proteasomal activity in COPD lung tissue may be attributed partly to the impaired Nrf2 signaling pathway. Furthermore, decline in the proteasome system suggests an impaired ability to remove oxidatively modified proteins in lungs of patients with COPD and underscores a new molecular mechanism in COPD pathogenesis.
As stated previously, oxidatively modified and misfolded proteins from the ER lumen are eliminated through ERAD by the proteasome system (43). Impaired proteasomal activity may trigger ER stress that activates the UPR signaling cascade. Accordingly, we observed greater activation of the UPR pathway, as reflected by higher levels of phosphorylated-eIFα2, in lungs of Nrf2−/− mice compared with Nrf2+/+ control mice after chronic CS exposure. Phosphorylated eIFα2a, a component of the PERK arm of the UPR, mediates attenuation of mRNA translation and reduces the burden of protein folding in the ER lumen. Paradoxically, in addition to general inhibition of protein synthesis, PERK up-regulates cytoprotective antioxidant defenses through phosphorylation of Nrf2 that occurs independently of eIFα2 phosphorylation (44). PERK-mediated Nrf2 phosphorylation has been demonstrated to be sufficient for disruption of the Nrf2/Kelch-like ECH-associated protein 1 interaction as well as nuclear translocation of Nrf2 (45, 46). Disruption of Nrf2 impairs PERK-mediated antioxidant induction and sensitizes cells to reactive oxygen species–induced cell death (46). Similarly, disruption of PERK ablates induction of Nrf2-dependent antioxidants, which suggests an indispensable role of Nrf2 in mediating PERK-induced cytoprotective signaling (47). Impaired resolution of ER stress results in PERK-mediated up-regulation of CHOP that induces apoptosis. Similarly, in this report we found that in contrast to Nrf2+/+ mice, CS-exposed emphysematous lungs of Nrf2−/− mice showed significantly higher expression of CHOP and correspondingly a greater level of apoptosis, as assessed by caspase activity. In accordance with the mouse data, we found greater levels of markers of ER stress with increasing severity of COPD. Levels of phosphorylated-eIF2α, CHOP, and caspase activity were elevated in the lungs of patients with mild COPD when compared with normal lungs and were further elevated in patients with advanced COPD. We previously reported an activation of the UPR pathway in the lungs of healthy human smoker lungs (10). Interestingly, we observed comparable levels of ER stress between ex-smokers and current smokers with advancing COPD, suggesting that ER stress persists after onset of COPD, irrespective of smoking history. Persistent ER stress in lungs of ex-smokers with COPD may be a result of a compromised UPR pathway, in part due to a defective Nrf2-regulated cytoprotective response. A role for other causal factors, such as viral infection, for induction of ER stress in COPD lungs cannot be ruled out (48–50). A recent study reported an absence of ER stress in lungs of patients with COPD (51). This contradicts present and previous reports that indicate (1) the propensity of CS condensate to induce ER stress and CHOP-mediated cell death in lung epithelial cells, and (2) existence of ER stress in human lungs from smokers and ex-smokers. Our data identify increased ER stress in lungs from patients with COPD and demonstrate a significant role of Nrf2 pathway in modulating the UPR pathway in COPD pathogenesis.
In lungs from smokers without COPD, both antioxidants and the proteasome-mediated cytoprotective pathways may modulate ER stress. To delineate the contribution of Nrf2-dependent antioxidants and/or proteasome system in limiting ER stress-mediated cellular dysfunction and cell death after CS exposure, we treated Nrf2+/+ mice with the proteasome inhibitor bortezomib. Bortezomib is used as an anticancer drug to induce cell death by increasing ER stress with a relative selectivity in cytotoxicity for malignant cells (52). Proteasome inhibition by bortezomib in mouse lungs significantly enhanced the expression of CS-induced markers of ER stress, P-eIF2α and CHOP expression, and increased cell death. These results indicate impaired proteasome function as one of the potential mechanisms for induction of ER stress in lungs from patients with COPD. Furthermore, they implicate a cross talk between ER stress and a compromised proteasome system in the pathogenesis of COPD, as predicted in other inflammatory disorders (53).
Alternatively, to determine whether the Nrf2-dependent proteasome system is vital in attenuating CS-induced ER stress and cell death, Beas2B cells were treated with the Nrf2 activator, sulforaphane (26). Sulforaphane treatment significantly enhanced proteasomal activity in Beas2B cells and attenuated CS-induced CHOP expression and cell death. However, proteasome inhibition post sulforaphane treatment significantly elevated CHOP expression and impaired cytoprotection in response to CS in Beas2B cells. Persistent ER stress also causes cellular dysfunction by disrupting synthesis of crucial secretory and membrane proteins via PERK/eIF2α pathway. CSC exposure significantly impaired the ER secretory pathway in Beas2B cells, as indicated by a decrease in secreted bioluminescent signal of Gluc in the conditioned media, which further worsened by proteasomal inhibition by bortezomib. On the contrary, sulforaphane pretreatment significantly improved secretion of Gluc after CSC treatment, which was also attenuated by proteasomal inhibition. Overall, our data suggest a critical role for the Nrf2-dependent proteasome system in inhibiting ER stress-induced cellular dysfunction and cell death.
To evaluate the role of Nrf2-regulated proteasome activity in inhibiting CS-induced ER stress and cytotoxicity, we overexpressed the catalytic subunit PSMB6 in Beas2B cells. Previous studies have demonstrated induction of proteasomal activity by overexpression of a similar catalytic proteasome subunit, PSMB5 (54). We observed that increasing proteasomal activity in Beas2B cells by overexpression of PSMB6 intrinsically enhanced resistance to ER stress and cell death after CSC treatment. This result underscores the cytoprotective role of the proteasome system in the lungs of smokers. The proteasome system is also involved in regulation of NF-κB activation by mediating degradation of phosphorylated IkB (55). Lungs of patients with COPD are associated with greater NF-κB activation when compared with normal control subjects (56). To understand whether enhancing Nrf2-dependent proteasome activity potentiates the CS-induced inflammatory response, we measured secreted IL-8 levels in Beas2B cells transfected with PSMB6. CSC treatment significantly increased secreted IL-8 levels; however, we noted no significant difference between vector and PSMB6-transfected Beas2B cells. This result suggests that up-regulation of Nrf2-dependent proteasomal activity may not affect the CS-induced inflammatory response.
In conclusion, we for the first time report a role for the Nrf2-mediated proteasome system in inhibiting ER stress–induced cytotoxicity in lungs of smokers with COPD, which may contribute to the pathogenesis of COPD. Future studies are warranted to determine the effect of ER stress on other cellular processes in COPD pathogenesis, such as impaired cellular repair, senescence, disruption in synthesis of extracellular matrix proteins and crucial secretory proteins such as surfactant proteins, and defective resolution of inflammation (57). In addition, more studies are required for selective targeting of the Nrf2 pathway to modify regulation of the proteasome system (Figure 8) as a robust strategy to disrupt COPD pathogenesis.
The authors would like to acknowledge Lung Tissue Research Consortium (LTRC) for providing the COPD lung tissue samples.
Supported by NIH grants RO1HL081205 (S.B.), SCCOR P50HL084945 (S.B.), Center for Childhood Asthma in the Urban Environment P50ES015903, P30 ES003819, Maryland Cigarette Restitution Fund (S.B.), Flight Attendant Medical Research Institute grant (S.B., A.N.), Cystic Fibrosis Foundation grants R025-CR07 and VIJ07IO (NV), and the NIH grant CTSA UL RR 025005 (NV), RHL096931 (NV).
This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org
Originally Published in Press as DOI: 10.1164/rccm.200903-0324OC on October 1, 2009
Conflict of Interest Statement: D.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. R.T. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. N.V. received $1,001–$5,000 from MedaCorp in consultancy fees. A.N.-A. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. T.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. L.Z. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.G.K. received $10,001–$50,000 as a member of the Data Safety monitoring board from Centocor, $1,001–$5,000 as a speaker from Genentech, $1,001–$5,000 as a speaker from AstraZeneca, $50,000–$100,000 from Genentech, more than $100,001 from GlaxoSmithKline, and $10,001–$50,000 from Novartis in sponsored grants. A.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. R.W. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. R.T. received up to $1,000 from Novartis in consultancy fees. S.B. received $5,001–$10,000 from Merck Frost in consultancy fees, up to $1,000 from Novartis in lecture fees, and more than $100,001 from Quark Pharmaceuticals in industry-sponsored grants.